Viridian Therapeutics, Inc./DE Debt Securities, Available-for-sale, Amortized Cost
Viridian Therapeutics, Inc./DE (VRDN) had Debt Securities, Available-for-sale, Amortized Cost of $817.70 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $817.70M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $586.39M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $661.82M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $481.07M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $817.70M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $586.39M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $661.82M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $481.07M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $552.69M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $627.85M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $618.00M 10-K · filed 2026-02-26 | $714.06M 10-K · filed 2025-03-03 |
| 2024-09-30 | $735.68M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $564.99M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $610.29M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $462.91M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $308.63M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $333.57M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $366.57M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $424.84M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $432.16M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $162.17M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $176.26M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $197.02M 10-K · filed 2023-03-09 | |
| 2020-12-31 | $127.71M 10-K · filed 2022-03-11 | |
| 2019-12-31 | $2.00M 10-Q · filed 2020-11-12 | |
| 2019-09-30 | $9.00M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $19.90M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $32.80M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $29.90M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |